University of Oklahoma College of Medicine Professor Doris Benbrook, Ph.D., has curated a new cancer drug, named OK-1 to treat and prevent ovarian, endometrial and cervical cancers.
After receiving FDA approval to be tested in a human phase I clinical trial, the drug showed little toxicity to patients while also shrinking tumors by attacking only unhealthy cells. This groundbreaking process leads to a less stressful and less painful treatment for most cases.
Upon further trials, the Oklahoma-made drug could be given to women with a genetic predisposition to cancer if OK-1 is shown to effectively prevent this disease.